My Portfolio
+
LINK YOUR PORTFOLIO

Brii Biosciences Ltd 2137-HK:Hong Kong Stock Exchange

*Data is delayed | Exchange | HKD
Last | 06/03/26 CTT
1.08UNCH (UNCH)
52 week range
1.07 - 2.54
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.08
  • 52 Week High2.54
  • 52 Week High Date08/18/25
  • 52 Week Low1.07
  • 52 Week Low Date06/03/26

Latest On Brii Biosciences Ltd

 

Key Stats

  • Market Cap779.552M
  • Shares Out721.81M
  • 10 Day Average Volume1.10M
  • Dividend-
  • Dividend Yield-
  • Beta1.62

Latest On Brii Biosciences Ltd

 

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.08
  • 52 Week High2.54
  • 52 Week High Date08/18/25
  • 52 Week Low1.07
  • 52 Week Low Date06/03/26
  • Market Cap779.552M
  • Shares Out721.81M
  • 10 Day Average Volume1.10M
  • Dividend-
  • Dividend Yield-
  • Beta1.62

RATIOS/PROFITABILITY

  • EPS (TTM)-0.34
  • P/E (TTM)-3.15
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-307.95M
  • ROE (TTM)-8.85%
  • Revenue (TTM)21.547M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,204.34%
  • Debt To Equity (MRQ)0.38%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Brii Biosciences Ltd is a biotechnology company primarily engaged in the development of therapies for infectious diseases and central nervous system diseases. The Company's main products include BRII-179, a candidate drug for hepatitis B virus (HBV) immunotherapy, Tobevibart, an investigational neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg), as well as soralimixin (BRII-693), a synthetic lipopeptide for treating multidrug-resistant (MDR) and...
Zhi Hong Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Ankang Li
Chief Financial Officer, Executive Director, Joint Company Secretary, Chief Strategy Officer, Chief Executive Officer of TSB
Address
3rd Floor, Building 7
Zhongguancun Dongsheng, International
No. 1 North Yongtaizhuang Road, Haidian
Beijing, BEJ
100192
China